Immuno-oncology Treatment Devices and Drugs Market Size & Share, by Treatment Type (Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus); Indication (Breast Cancer, Lung Cancer, Blood Cancer, Melanoma, Head & Neck Cancer, Prostate Cancer and Others); End-User - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 2940
  • Published Date: Sep 23, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Immuno-oncology Treatment Devices and Drugs Market size is set to expand at significant growth rate during the forecast period i.e., between 2024-2036. 

The increasing prevalence of cancer globally, along with the growing investments in the healthcare sector are expected to fuel the development of this market in the near future. The growth of the market can also be attributed to factors such as the increasing geriatric population and an increase in exposure to cancer risk factors linked to social and economic development. According to the WHO, cancer is currently the second leading cause of death worldwide. As per their the Globocan report, global cancer burden is estimated to have risen to 19.3 million cases and 10 million cancer-related deaths in 2020.


Global-Immuno-Oncology-Treatment-and-Drug-Market-Share
Get more information on this report: Request Free Sample PDF

Immuno-oncology Treatment Devices and Drugs Sector: Growth Drivers and Challenges

Growth Drivers

  • Rising Prevalence of Cancer
  • Increasing Demand for Monoclonal Antibodies

Challenges

  • High Cost Associated with the Treatment
  • Lack of Awareness about the Treatment in Lower Income Regions

Immuno-oncology Treatment Devices and Drugs Market: Key Insights

Base Year

2023

Forecast Year

2024–2036

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Immuno-oncology Treatment Devices and Drugs Segmentation

The immuno-oncology treatment devices and drugs market is segmented based on treatment type into immune checkpoint inhibitors, immune system modulators, cancer vaccines, oncolytic virus, and others, out of which, the immune checkpoint inhibitors segment is anticipated to grab the largest market share by the end of 2029 on account of its high level of specificity and lesser side-effects. Moreover, increasing government approval for new treatments and drugs globally is also projected to contribute to the growth of the segment during the forecast period.

On the basis of indication, the breast cancer segment in the immuno-oncology treatment devices and drugs market is projected to grow with a high CAGR over the forecast period. Obesity, lack of physical exercise, overexposure to radiation, and increased alcohol consumption are some of the major risk factors causing breast cancer in females. According to Globocan report 2020, the incidence rate of breast cancer was 5.20% which accounted for 2.26 million new cases globally with a mortality rate of 6.9%.

Based on end-user, the hospital segment held the largest share in the immuno-oncology treatment devices and drugs market on the back of increasing patient influx and increasing spending by the hospitals on immuno-oncological treatments. 

 

Our in-depth analysis of the global market includes the following segments:

          Treatment Type

  • Immune Checkpoint Inhibitors
    • PD-1
    • PD-L1
    • CTLA-4
  • Immune System Modulators
  • Cancer Vaccines
  • Oncolytic Virus
  • Others

          By Indication

  • Breast Cancer
  • Lung Cancer
  • Blood Cancer
  • Melanoma
  • Head & Neck Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Others

          End-User

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Others

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Immuno-oncology Treatment Devices and Drugs Industry - Regional Synopsis

Geographically, the immuno-oncology treatment devices and drugs market is segmented into North America, Latin America, Europe, Asia Pacific and the Middle East & Africa region. The market in the Asia Pacific industry is expected to dominate majority revenue share by 2036, owing to increasing birth rates, and rising geriatric population in the region. Furthermore, the market in North America is evaluated to occupy the largest share in terms of revenue during the forecast period, owing to the growing healthcare investment, accompanied by the presence of leading healthcare service providers, and the increasing prevalence of cancer in the region. Along with this, the countries in North America such as the United States is promoting nutritional care for cancer patients, which is also expected to contribute to the market growth in the region. According to the report published by the National Cancer Institute, in 2020, 1.8 million new cancer cases were registered in the United States. Such increasing rate of cancer is further expected to drive the demand for immuno-oncology treatment devices and drugs products in the North American countries. Alternatively, the market in Europe is also anticipated to occupy a significant share in the immuno-oncology treatment devices and drugs market on account of its proven success in terms of technology development and a high prevalence of cancer in the region. As per the analysis of the European Society for Medical Oncology, 2.7 million new cancer cases were registered in the European Union, with 1.3 million deaths in 2020.

Research Nester
Immuno-Oncology-Treatment-and-Drugs-Market-Share
Get more information on this report: Request Free Sample PDF

Companies Dominating the Immuno-oncology Treatment Devices and Drugs Landscape

    •  F. Hoffmann-La Roche Ltd
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Merck & Company, Inc.
    • AstraZeneca Plc.
    • Novartis AG
    • Amgen Inc.
    • Pfizer Inc.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Janssen Global Services, LLC
    • GlaxoSmithKline plc

Author Credits:  Radhika Pawar


  • Report ID: 2940
  • Published Date: Sep 23, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Rising prevalence of cancer and increasing demand for monoclonal antibodies are the key factors driving market growth.

The market is anticipated to attain a moderate CAGR over the forecast period, i.e., 2021-2029.

Lack of awareness and high-cost associated with the immune-oncological treatment are estimated to hamper market growth.

The market in Asia Pacific region will provide ample growth opportunities owing to rising geriatric population and increasing cancer prevalence.

The major players dominating the immune-oncology treatment devices and drugs market are F. Hoffmann-La Roche Ltd, Merck & Company, Inc., AstraZeneca Plc., Novartis, Amgen Inc., Pfizer Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Janssen, GlaxoSmithKline plc., and others.
Immuno-oncology Treatment Devices and Drugs Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample